Company Overview

Founded in 1966, Lotus is a leading generic company headquartered in Taiwan with comprehensive product portfolio covering CNS, CVS, oncology, women health, and anti-obesity drugs in tablets & hard/softgel capsules. Lotus runs the only plant in Taiwan approved by US FDA, EU EMA, and Japan PMDA. The Company started a new phase of growth in 2014 when Alvogen, a next generation, global pharmaceutical company, became a majority shareholder and hand picked Taiwan as its Regional Asian Headquarters. Lotus now is a fast growing specialty generic company in Asia. Our business model ensures competitive advantage through focused in-house capabilities and a network of partners for enhanced speed and flexibility. Through its majority shareholder Alvogen, Lotus has access to markets in the USA, Central Eastern Europe and Asia, while on its own Lotus has presence in Asia in Korea, Taiwan, China, India and exports to Japan and South East Asia.

Development Projects
Pending ANDA filings

Asia Pacific Footprints

Broad range of countries

Being the regional hub in Asia Pacific of Alvogen, Lotus’ international footprints currently encompass a broad range of countries including Korea, Myanmar, Thailand, Vietnam, Philippines, Singapore, Malaysia, Hong Kong,China, through its own and Alvogen’s affiliates, with headquarters in Taiwan. Lotus has manufacturing and R&D hubs in Taiwan and Korea.

Operations in Asia

Meet management


Lotus is led by a globally experienced management team. With support from Alvogen, Lotus management is poised to lead Lotus to become a leading generic company among the top 5 in Asia.


Alvogen Partnership 

Alvogen currently has commercial operations in 35 countries around the globe, with regional hubs based in North America, Romania, and Taiwan, and is ready well advanced in the field of biopharmaceuticals and currently markets several biosimilars in selected regions through strategic alliances. Over US$500 million are being invested in the development of monoclonal antibodies and state-of-the-art manufacturing capabilities, and the team is committed to continuing to grow our business around the world and to becoming a top 10 global generic pharmaceuticals player. 

Visit Alvogen

Among the top 5 in Asia

Our passionate team is committed to continue to grow our business and we aim to become a leading generic company among the top 5 in Asia.


Lotus has operations in 10 countries within Asian region through its own and Alvogen’s affiliates, with manufacturing and R&D capabilities in Taiwan and Korea.

Connect with local teams to learn more about product offering in your region.

Operations in Asia